News Releases All 2024 2023 2022 2021 2020 2019 2024.01.04 Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 6 - 6 of 6
2024.01.04 Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium